Scarica l'app Stockscreener
29.46
2.47%
0.71
Dopo l'orario di chiusura:
29.46
Maplight Therapeutics Inc Borsa (MPLT) Ultime notizie
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - AOL.com
Nan Fung Group Holdings Ltd's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus
MPLT Initiated Coverage On by Craig-Hallum -- Rating Set to Buy - GuruFocus
Craig-Hallum initiates MapLight Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Craig-Hallum initiates coverage of MapLight Therapeutics (MPLT) with buy recommendation - MSN
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock By Investing.com - Investing.com Nigeria
MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing - Moomoo
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock - Investing.com
MapLight Therapeutics (MPLT) CEO sells 118K shares in pre-planned trades - Stock Titan
MapLight Therapeutics, Inc.Common Stock (NQ: MPLT - The Chronicle-Journal
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged - TipRanks
T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics - Stock Titan
A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $35 to $45 - Moomoo
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36, Implies 23% Upside - TradingView
MapLight (MPLT) Reports Progress in Clinical Trials and Early-St - GuruFocus
MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses - TipRanks
MapLight Therapeutics 1Q Loss/Shr $1.34 >MPLT - Moomoo
[10-Q] MapLight Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
MapLight Therapeutics (MPLT) widens Q1 loss as key Phase 2 readouts near - Stock Titan
What $395M in cash means for MapLight’s schizophrenia, autism trials - Stock Titan
MapLight Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MapLight Therapeutics CEO Christopher Kroeger sells $1.95 million in stock By Investing.com - Investing.com Australia
MapLight Therapeutics CSO Lillie Woodruff sells $20,389 of company stock - Investing.com UK
MapLight Therapeutics CSO Lillie Woodruff sells $20,389 of company stock By Investing.com - Investing.com Australia
MapLight Therapeutics CMO Foff sells $126,639 in stock - Investing.com UK
MapLight Therapeutics general counsel Kristopher Hanson sells $419,263 By Investing.com - Investing.com Canada
MapLight Therapeutics CMO Foff sells $126,639 in stock By Investing.com - Investing.com South Africa
MapLight Therapeutics CEO Christopher Kroeger sells $1.95 million in stock - Investing.com UK
MapLight Therapeutics general counsel Kristopher Hanson sells $419,263 - Investing.com India
MapLight Therapeutics (MPLT) CSO sells 721 shares in planned trade - Stock Titan
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2026 - MarketBeat
MapLight Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
MapLight plans two New York investor events with live webcasts - Stock Titan
Maplight Therapeutics Insider Sold Shares Worth $1,427,594, According to a Recent SEC Filing - Moomoo
Maplight Therapeutics Insider Sold Shares Worth $1,024,719, According to a Recent SEC Filing - Moomoo
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):